Maxim Group Lowers Indaptus Therapeutics (NASDAQ:INDP) Price Target to $5.00

Indaptus Therapeutics (NASDAQ:INDP) had its price target lowered by Maxim Group from $8.00 to $5.00 in a report issued on Wednesday,Benzinga reports. The brokerage currently has a buy rating on the stock.

Separately, HC Wainwright reaffirmed a “buy” rating and issued a $12.00 price objective on shares of Indaptus Therapeutics in a research note on Wednesday, October 16th.

Indaptus Therapeutics Trading Down 1.3 %

Shares of Indaptus Therapeutics stock opened at $1.11 on Wednesday. The firm has a market cap of $11.32 million, a PE ratio of -0.65 and a beta of 1.45. Indaptus Therapeutics has a 12 month low of $1.03 and a 12 month high of $3.10. The stock has a 50 day moving average of $1.31 and a 200 day moving average of $1.82.

Indaptus Therapeutics (NASDAQ:INDP) last posted its quarterly earnings data on Tuesday, November 12th. The company reported ($0.32) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.47) by $0.15. As a group, equities research analysts forecast that Indaptus Therapeutics will post -1.79 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Indaptus Therapeutics

A hedge fund recently bought a new stake in Indaptus Therapeutics stock. Virtu Financial LLC purchased a new position in Indaptus Therapeutics, Inc. (NASDAQ:INDP) during the 1st quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor purchased 14,232 shares of the company’s stock, valued at approximately $32,000. Virtu Financial LLC owned 0.17% of Indaptus Therapeutics as of its most recent filing with the Securities and Exchange Commission (SEC). Institutional investors and hedge funds own 7.06% of the company’s stock.

About Indaptus Therapeutics

Indaptus Therapeutics, Inc, a clinical biotechnology company, develops various anti-cancer and anti-viral immunotherapy products. Its lead clinical candidate is Decoy20 used to produce single agent activity and/or combination therapy-based durable responses of lymphoma, hepatocellular, colorectal, and pancreatic tumors, and chronic hepatitis B virus, and human immunodeficiency virus infection, which is in Phase 2 clinical trial.